DNAPrint Genomics Stock Forward View - Simple Exponential Smoothing
DNAPrint Stock outlook is based on your current time horizon. We recommend always using this module together with an analysis of DNAPrint Genomics' historical fundamentals, such as revenue growth or operating cash flow patterns.
As of 30th of January 2026 the rsi of DNAPrint Genomics' share price is below 20 suggesting that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Quarterly Revenue Growth (0.65) |
Using DNAPrint Genomics hype-based prediction, you can estimate the value of DNAPrint Genomics from the perspective of DNAPrint Genomics response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Exponential Smoothing forecasted value of DNAPrint Genomics on the next trading day is expected to be 0.00 with a mean absolute deviation of 0.00 and the sum of the absolute errors of 0.00. DNAPrint Genomics after-hype prediction price | USD 0.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of DNAPrint Genomics to cross-verify your projections. DNAPrint Genomics Additional Predictive Modules
Most predictive techniques to examine DNAPrint price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for DNAPrint using various technical indicators. When you analyze DNAPrint charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
DNAPrint Genomics Simple Exponential Smoothing Price Forecast For the 31st of January
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of DNAPrint Genomics on the next trading day is expected to be 0.00 with a mean absolute deviation of 0.00, mean absolute percentage error of 0.00, and the sum of the absolute errors of 0.00.Please note that although there have been many attempts to predict DNAPrint Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that DNAPrint Genomics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
DNAPrint Genomics Stock Forecast Pattern
| Backtest DNAPrint Genomics | DNAPrint Genomics Price Prediction | Buy or Sell Advice |
DNAPrint Genomics Forecasted Value
In the context of forecasting DNAPrint Genomics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. DNAPrint Genomics' downside and upside margins for the forecasting period are 0.00 and 0.00, respectively. We have considered DNAPrint Genomics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of DNAPrint Genomics stock data series using in forecasting. Note that when a statistical model is used to represent DNAPrint Genomics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | -9.223372036854776E14 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0 |
| MAPE | Mean absolute percentage error | 0.0 |
| SAE | Sum of the absolute errors | 0.0 |
Predictive Modules for DNAPrint Genomics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as DNAPrint Genomics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.DNAPrint Genomics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as DNAPrint Genomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DNAPrint Genomics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with DNAPrint Genomics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 0 Events / Month | 1 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.00 | 0.00 | 0.00 |
|
DNAPrint Genomics Hype Timeline
DNAPrint Genomics is currently traded for 0.00. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. DNAPrint is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on DNAPrint Genomics is about 0.0%, with the expected price after the next announcement by competition of 0.00. The company had not issued any dividends in recent years. DNAPrint Genomics had 1:20 split on the 12th of July 2005. Given the investment horizon of 90 days the next forecasted press release will be in a few days. Check out Historical Fundamental Analysis of DNAPrint Genomics to cross-verify your projections.DNAPrint Genomics Related Hype Analysis
Having access to credible news sources related to DNAPrint Genomics' direct competition is more important than ever and may enhance your ability to predict DNAPrint Genomics' future price movements. Getting to know how DNAPrint Genomics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how DNAPrint Genomics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| USRM | US Stem Cell | 0.00 | 3 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| IPAH | Interpharm Holdings | 0.00 | 2 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| LADX | LadRx | 0.00 | 0 per month | 16.78 | 0.15 | 53.85 | (9.09) | 1,009 | |
| AVXT | Avax Techs | 0.00 | 1 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MOBO | Mobile Lads Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BRAXF | Braxia Scientific Corp | 0.00 | 0 per month | 0.00 | (0.13) | 0.00 | 0.00 | 92.31 | |
| REFG | Medical Cannabis Pay | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MRPI | Mera Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| JNHMF | Jack Nathan Medical | 0.00 | 0 per month | 0.00 | 0.12 | 0.00 | 0.00 | 800.00 | |
| MHTX | Manhattan Scients | 0.00 | 1 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Forecasting Options for DNAPrint Genomics
For every potential investor in DNAPrint, whether a beginner or expert, DNAPrint Genomics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. DNAPrint Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in DNAPrint. Basic forecasting techniques help filter out the noise by identifying DNAPrint Genomics' price trends.DNAPrint Genomics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with DNAPrint Genomics stock to make a market-neutral strategy. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Story Coverage note for DNAPrint Genomics
The number of cover stories for DNAPrint Genomics depends on current market conditions and DNAPrint Genomics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that DNAPrint Genomics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about DNAPrint Genomics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Check out Historical Fundamental Analysis of DNAPrint Genomics to cross-verify your projections. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.